2H3-leucine

Investigated by: Mayo Clinic · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · National Institutes of Health (NIH) · Rare Diseases Clinical Research Network

today NCT02038543 · Ph 1/2

20142015201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1/2	NCT02038543	Sep 2013 → Sep 2016	primary hyperoxaluria	Mayo Clinic	Completed	No outcome recorded

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	2H3-leucine	“Subjects will be infused with 13C5-hydroxyproline and 2H3-leucine for 6 hrs in the Clinical Research and Trials Unit (CRTU).” NCT02038543 ↗